Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

MRSN


Top 10 Correlated ETFs

MRSN


Top 10 Correlated Stocks

MRSN


In the News

12:03 29 Nov 2022 MRSN

Mersana Therapeutics, Inc. (MRSN) Q3 2022 Earnings Call Transcript

Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q3 2022 Earnings Conference Call November 7, 2022 8:30 AM ET Company Participants Jason Fredette - Senior Vice President, Investor Relations and Corporate Communications Anna Protopapas - President and Chief Executive Officer Arvin Yang - Senior Vice President and Chief Medical Officer Brian DeSchuytner - Senior Vice President and Chief Financial Office Conference Call Participants Jonathan Chang - SVB Securities Colleen Kusy - Baird Kaveri Pohlman - BTIG David Nierengarten - Wedbush Boris Peaker - Cowen & Co Operator Good morning, and welcome to Mersana Therapeutics Third Quarter 2022 Conference Call and webcast. Currently, all participants are in a listen-only mode.

09:48 29 Nov 2022 MRSN

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -1,933.33% and 85.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

09:27 29 Nov 2022 MRSN

Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed

Shares of Mersana Therapeutics are up 21% in 2022 and +168% over the past 3 years. Management sees lead antibody drug conjugate UpRi gaining broad use in ovarian cancer, though I remain skeptical.

10:36 29 Nov 2022 MRSN

Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q2 2022 Results - Earnings Call Transcript

Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Jason Fredette - Senior Vice President, Investor Relations and Corporate Communications Anna Protopapas - President, CEO & Director Arvin Yang - Senior VP & Chief Medical Officer Brian DeSchuytner - Senior VP & CFO Conference Call Participants Jonathan Chang - SVB Securities Colleen Kusy - Baird Operator Good afternoon, and welcome to Mersana Therapeutics Second Quarter 2022 Conference Call and webcast. Currently, all participants are in a listen-only mode.

06:48 29 Nov 2022 MRSN

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Tops Revenue Estimates

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -10% and 34.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

08:00 29 Nov 2022 MRSN

Mersana Therapeutics to Host Second Quarter 2022 Conference Call on August 8, 2022 and Present at Upcoming Conferences

CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report financial results for the second quarter ended June 30, 2022 on Monday, August 8, 2022 and will host a conference call and webcast at 4:30 p.m. Eastern Time that afternoon. Members of management will also be presenting at two upcoming conferences. Details are as follows:

11:36 29 Nov 2022 MRSN

How Much Upside is Left in Mersana Therapeutics, Inc. (MRSN)? Wall Street Analysts Think 256%

The mean of analysts' price targets for Mersana Therapeutics, Inc. (MRSN) points to a 255.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

08:00 29 Nov 2022 MRSN

Mersana Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at three upcoming investor conferences. Details are as follows:

11:19 29 Nov 2022 MRSN

Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q1 2022 Results - Earnings Call Transcript

Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q1 2022 Earnings Conference Call May 9, 2022 8:00 AM ET Company Participants Jason Fredette - Senior Vice President, Investor Relations and Corporate Communications Anna Protopapas - President, CEO & Director Arvin Yang - Senior VP & Chief Medical Officer Tim Lowinger - Chief Science & Technology Officer Brian DeSchuytner - Senior VP & CFO Conference Call Participants Jonathan Chang - SVB Leerink Boris Peaker - Cowen Daniel Wolle - JPMorgan Colleen Kusy - Baird David Nierengarten - Wedbush Securities Operator Good morning, and welcome to Mersana Therapeutics First Quarter 2022 Conference Call and webcast. Currently all participants are in a listen-only mode.

09:51 29 Nov 2022 MRSN

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -90.32% and 89.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Financial details

Company Rating
Buy
Market Cap
651.52M
Income
-208.27M
Revenue
11.9M
Book val./share
0.92
Cash/share
2.97
Dividend
-
Dividend %
-
Employees
169
Optionable
No
Shortable
Yes
Earnings
07 Nov 2022
P/E
-2.62
Forward P/E
-3.53
PEG
-0.37
P/S
53.56
P/B
7.07
P/C
2.19
P/FCF
-15.14
Quick Ratio
3.27
Current Ratio
3.38
Debt / Equity
0.38
LT Debt / Equity
0.38
-
-
EPS (TTM)
-2.43
EPS next Y
-1.84
EPS next Q
-0.62
EPS this Y
65.74%
EPS next Y
-24.28%
EPS next 5Y
-24.28%
EPS last 5Y
-5.95%
Revenue last 5Y
-69.95%
Revenue Q/Q
30.09%
EPS Q/Q
10.91%
-
-
-
-
SMA20
-8.15%
SMA50
-13.72%
SMA100
34.85%
Inst Own
96.27%
Inst Trans
-3.73%
ROA
-66%
ROE
-171%
ROC
-0.91%
Gross Margin
36%
Oper. Margin
-1730%
Profit Margin
-1750%
Payout
-
Shs Outstand
97.17M
Shs Float
70.61M
-
-
-
-
Target Price
19
52W Range
2.68-8.338
52W High
-18.75%
52W Low
+225%
RSI
44.25
Rel Volume
0.55
Avg Volume
1.05M
Volume
573.78K
Perf Week
-3.7%
Perf Month
-1.22%
Perf Quarter
91.18%
Perf Half Y
94.61%
-
-
-
-
Beta
1.71672
-
-
Volatility
0.07%, 0.43%
Prev Close
-0.46%
Price
6.5
Change
-1.52%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
1.460.460.970.010
Net income per share
-3.22-2.79-0.65-1.43-2.37
Operating cash flow per share
-3.55-2.4-1.56-1.21-1.95
Free cash flow per share
-3.64-2.46-1.57-1.22-1.96
Cash per share
9.543.042.294.152.48
Book value per share
5.820.381.83.711.7
Tangible book value per share
5.820.381.83.711.7
Share holders equity per share
5.820.381.83.711.7
Interest debt per share
000.120.10.55
Market cap
180.58M105.49M303.57M1.17B309.97M
Enterprise value
153.99M45.85M246.09M922.46M170.2M
P/E ratio
-4.67-1.64-10.76-13.31-1.82
Price to sales ratio
10.299.967.211.42K7.21K
POCF ratio
-4.23-1.91-4.48-15.69-2.21
PFCF ratio
-4.12-1.86-4.44-15.59-2.2
P/B Ratio
2.5811.993.885.142.55
PTB ratio
2.5811.993.885.142.55
EV to sales
8.784.335.841.11K3.96K
Enterprise value over EBITDA
-4.08-0.73-9.21-10.64-1.01
EV to operating cash flow
-3.61-0.83-3.63-12.35-1.22
EV to free cash flow
-3.51-0.81-3.6-12.27-1.21
Earnings yield
-0.21-0.61-0.09-0.08-0.55
Free cash flow yield
-0.24-0.54-0.23-0.06-0.45
Debt to equity
000.050.020.29
Debt to assets
0.460.890.270.170.41
Net debt to EBITDA
0.70.952.152.880.83
Current ratio
3.691.074.218.623.97
Interest coverage
00-129.06-245.43-133.27
Income quality
1.10.862.40.850.82
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.61.540.4126.45857.86
Research and developement to revenue
2.665.661.3180.963.07K
Intangibles to total assets
00000
Capex to operating cash flow
0.030.020.010.010
Capex to revenue
-0.07-0.13-0.01-0.57-15.07
Capex to depreciation
-1.23-1.09-0.49-0.47-0.76
Stock based compensation to revenue
0.080.370.128.66428.12
Graham number
20.544.95.1310.939.51
ROIC
-0.4-7.23-0.36-0.36-1.06
Return on tangible assets
-0.3-0.82-0.26-0.32-0.83
Graham Net
4.540.031.623.411.3
Working capital
85.66M4.88M77.26M228.58M141.38M
Tangible asset value
00000
Net current asset value
56.82M4.6M72.1M213.27M104.53M
Invested capital
000.060.020.31
Average receivables
00000
Average payables
5.71M9.53M7.82M8.34M10.33M
Average inventory
00000
Days sales outstanding
16.3115.81000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
22.3823.08000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.55-7.31-0.36-0.39-1.4
Capex per share
-0.1-0.06-0.01-0.01-0.01

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
000.030.040.06
Net income per share
-0.63-0.68-0.59-0.55-0.61
Operating cash flow per share
-0.5-0.59-0.1-0.470.56
Free cash flow per share
-0.5-0.59-0.1-0.470.55
Cash per share
2.672.472.882.352.97
Book value per share
2.171.691.761.40.92
Tangible book value per share
2.171.691.761.40.92
Share holders equity per share
2.171.691.761.40.92
Interest debt per share
0.270.540.480.40.39
Market cap
676.63M447.35M318.92M442.4M660.06M
Enterprise value
504.14M307.58M126.53M344.49M512.82M
P/E ratio
-3.72-2.28-1.69-2.12-2.76
Price to sales ratio
61.51K40.67K156.64103.27118.44
POCF ratio
-18.74-10.55-40.09-9.8812.09
PFCF ratio
-18.72-10.51-38.5-9.7412.18
P/B Ratio
4.353.672.273.37.32
PTB ratio
4.353.672.273.37.32
EV to sales
45.83K27.96K62.1580.4192.02
Enterprise value over EBITDA
-11.16-6.44-2.73-6.72-8.73
EV to operating cash flow
-13.97-7.25-15.91-7.699.39
EV to free cash flow
-13.95-7.23-15.27-7.589.47
Earnings yield
-0.07-0.11-0.15-0.12-0.09
Free cash flow yield
-0.05-0.1-0.03-0.10.08
Debt to equity
0.110.290.250.260.38
Debt to assets
0.290.410.460.470.71
Net debt to EBITDA
3.822.924.151.912.51
Current ratio
4.533.974.283.323.38
Interest coverage
-463.14-48.96-64.3-68.09-67.77
Income quality
0.790.870.170.86-0.91
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
920.36970.366.283.462.61
Research and developement to revenue
3.21K3.4K17.599.629.09
Intangibles to total assets
00000
Capex to operating cash flow
000.040.01-0.01
Capex to revenue
-4.18-14.09-0.16-0.15-0.08
Capex to depreciation
-0.22-0.73-1.6-2.89-2
Stock based compensation to revenue
448441.822.691.250.96
Graham number
5.565.094.844.143.57
ROIC
-0.26-0.3-0.23-0.29-0.26
Return on tangible assets
-0.21-0.24-0.18-0.21-0.19
Graham Net
1.811.31.411.120.67
Working capital
155.33M141.38M185.01M165.61M211.24M
Tangible asset value
00000
Net current asset value
137.32M104.53M123.73M118.76M75.42M
Invested capital
0.120.310.270.280.41
Average receivables
00000
Average payables
7.01M10.24M8.97M8.16M10.95M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.29-0.4-0.34-0.39-0.66
Capex per share
000-0.010

Frequently Asked Questions

What is Mersana Therapeutics, Inc. stock symbol ?

Mersana Therapeutics, Inc. is a US stock , located in Cambridge of Massachusetts and trading under the symbol MRSN

What is Mersana Therapeutics, Inc. stock quote today ?

Mersana Therapeutics, Inc. stock price is $6.5 today.

Is Mersana Therapeutics, Inc. stock public?

Yes, Mersana Therapeutics, Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap